Tudor Investment Corp ET AL Reduces Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Tudor Investment Corp ET AL cut its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 39.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 305,186 shares of the company's stock after selling 202,171 shares during the quarter. Tudor Investment Corp ET AL owned about 0.20% of Xeris Biopharma worth $1,035,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in XERS. NewEdge Advisors LLC purchased a new stake in shares of Xeris Biopharma during the fourth quarter valued at $34,000. R Squared Ltd purchased a new stake in Xeris Biopharma during the 4th quarter valued at about $42,000. Cibc World Markets Corp acquired a new position in shares of Xeris Biopharma in the fourth quarter valued at about $44,000. Raymond James Financial Inc. purchased a new position in shares of Xeris Biopharma in the fourth quarter worth about $45,000. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Xeris Biopharma during the fourth quarter worth about $50,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Craig Hallum raised their price target on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research report on Friday, March 7th. Leerink Partners boosted their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research report on Friday, March 7th. Piper Sandler reaffirmed a "neutral" rating and set a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Jefferies Financial Group restated a "buy" rating and issued a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Finally, HC Wainwright reiterated a "buy" rating and set a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $6.10.

Insider Buying and Selling at Xeris Biopharma

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total transaction of $217,200.00. Following the transaction, the insider now directly owns 1,353,510 shares of the company's stock, valued at $7,349,559.30. This trade represents a 2.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.56% of the stock is owned by corporate insiders.

Xeris Biopharma Stock Down 7.3 %

NASDAQ:XERS opened at $4.30 on Wednesday. The stock has a market capitalization of $672.46 million, a PE ratio of -9.56 and a beta of 1.10. Xeris Biopharma Holdings, Inc. has a 52 week low of $1.72 and a 52 week high of $6.07. The stock's 50-day moving average price is $4.59 and its 200-day moving average price is $3.82.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.